Inclusion Criteria:

- Patients with histologically confirmed L-sarcomas (leiomyosarcoma and liposarcoma)

- Measurable disease according to RECIST 1.1

- Any treatment line except adjuvant setting: evidence of primary metastatic situation
or disease progression within the last 6 months (based on RECIST 1.1) in computed
tomography or magnetic resonance imaging

- Any prior treatment possible

- Age >= 18 years

- WHO PS =< 1

- Effective contraception during study medication and up to 3 months from treatment
discontinuation

- Signed informed consent form

Exclusion Criteria:

- Surgical intervention < 4 weeks

- Pregnancy or lactation

- Known allergic reaction to trabectedin or gemcitabine or one of their components

- The following laboratory values:

Absolute neutrophil count < 1.5 x 103/mm3 Platelets < 100.000/mm3 Hb < 9 g/dL Serum
creatinine >= 2.5 mg/dl SGOT and/or SGPT and/or alkaline phosphatase and/or CPK > 2.5 x
ULN Total bilirubin > 1 x ULN except in the case of Gilbert's syndrome

- Participation in another study (four weeks before and during the study)

- Prior malignancy apart from completely resected basal cell carcinoma of the skin or
carcinoma in situ of the uterine cervix